Accolade — Investor Presentation (October 2021)
29 slides from Accolade's investor presentation, October 2021
Slide 1: Accolade Investor Presentation
Accolade Investor Presentation October 2021 NASDAQ: ACCD
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b
Slide 3: Our Mission, Our Vision
Our Mission Our mission is to empower people through expertise, empathy, and technology to make the best decisions for their health and well-being. Our Vision Our vision is every person living their healthiest life.
Slide 4: Healthcare is a human experience
We believe: Healthcare is a human experience
Slide 5: Value-based care over transactional care
We believe: Value-based care over transactional care
Slide 6: The Cost of a Poor Healthcare Experience
The Cost of a Poor Healthcare 76% of people don’t understand their available Experience benefits or how they work 88% of workers reported extreme stress, compared to 16% before the onset of COVID $225.88B in lost workforce productivity due to poor healthcare and preventable chronic conditions cost U
Slide 7: The healthcare system isn't designed for experience
The healthcare system isn’t designed for experience. The healthcare we have The healthcare we need need Transactional Holistic Disempowering Human centered Opaque Inclusive Biased Data driven and personalized Wasteful Value based
Slide 8: Personalized Healthcare
Personalized Healthcare Personal | Data Driven | Value Based
Slide 9: Delivering Value Across the Entire Healthcare Journey
Delivering Value Across the Entire Healthcare Journey Benefits Education, Utilization and Engagement Provider Selection, Care Delivery and Support Annual Open Enrollment Schedule appointment Verify benefits Address medical Research bills and ongoing Engage in care plan options treatment costs manage
Slide 10: Accolade Solutions
Accolade Solutions Accolade Accolade Accolade Accolade Care Expert MD Advocacy One Same-day access Real-time expert Personalized, Value-based care to virtual primary consultations for trusted guidance that deeply and mental and education for integrates advocacy, members facing virtual primary care,
Slide 11: A Truly Powerful, Personalized Healthcare Platform
A Truly Powerful, Personalized Healthcare Platform Personal | Data Driven | Value Based 24/7 Care Team Care EQ True Health Engine True Health Action Plan It’s a long-term Building trust. The right data. The right next steps. relationship.
Slide 12: Engaging Members and Providers
Engaging Members and Providers % Assisted %Provider Engagement Total Contacts 25 100% 98% 94% 93% 90% 79% 20 80% 70% 62% 15 60% 52% 42% 40% 40% 10 29% 20% 20% 5 0% 0 0 - $2500 $2.5k - $10k $10k to $25k $25k to $50k $50k to $100k $100k+ Low-spend Families Middle-spend Families High-spend Families Nur
Slide 13: Engaging the Ecosystem
Engaging the Ecosystem Connecting members to the right program, at the right time, in the right way * Tuition Reimbursement Apps and EAP Portals Travel Insurance PBMs 401k Wellness and Health Optimizers Discount Benefits Programs Telehealth and Admin 2nd Opinion Accolade ©2021 - Confidential 13
Slide 14: Quadruple Aim
Quadruple Aim Better Patient Outcomes Satisfaction At Accolade, we’re improving clinical outcomes, lowering healthcare costs, improving patient satisfaction, and improving care team Reduced Physician Costs Experience and clinician satisfaction.
Slide 15: The Future
The Future
Slide 16: Accelerating Accolade's Clinical Innovation
Accelerating Accolade’s Clinical Innovation Lowering Healthcare Spend 2021 SEPTEMBER Introduced Personalized JUNE Healthcare – Accolade One 2020 Added PlushCare - and Accolade Care MARCH Virtual Primary Care Added 2nd.MD - SEPTEMBER Expert Medical Opinion 2007 - 2019 Launched Mental Health Integrate
Slide 17: Significantly Expanded Addressable Market $216 billion
Significantly Expanded Addressable Market $216 billion TAM 450 Customers 400+ $170BN 400 Primary Care 350 300 250 $22BN 200 Expert Medical Opinion 150 112 100 54 $24BN 50 Navigation & Advocacy 15 20 0 FY2018 FY2019 FY2020 FY2021 Combined Source: Company Estimates and Piper Sandler
Slide 18: Growth Strategy
Compelling Growth Strategy Grow customer base Further penetrate our market of 30,000+ self- and fully insured employers Retain and expand Grow relationships especially through the sale of new solutions, and add-on services such as Virtual Primary Care and customer relationships Expert Medical Opinio
Slide 19: Financials
Financials
Slide 20: Financial Highlights
Financial Highlights ARR Bookings driving substantial revenue growth 29% revenue growth rate FY2020 to FY2021; Ended FY21 with $211mm ACV PMPM recurring revenue model provides significant revenue visibility Multi-year contracts with base + performance-based PMPM fees; demonstrated renewals Adjusted
Slide 21: Strong Revenue Growth
Strong Revenue Growth Predictable, highly visible, and recurring revenue Revenue and FYE ACV Quarterly Revenue $ millions $ millions Revenue ACV at FYE $303 - $307* $80 FY20 FY21 FY22 $300 $73.3 $74.5 - $76.5* $70 R $250 AG %C $ 59.5 $59.2 +34 $60 A GR $211 $200 2%C +3 $50 $170.4 $44.4 $161 $38.4 $1
Slide 22: Annual Result Trends
Annual Result Trends Revenue Adjusted Gross Profit and $170.4 mm Adjusted Gross Profit Margin $132.5 mm $77.6 mm $94.8 mm $59.1 mm $34.5 mm 36.4% 44.6% 45.6% FY19 FY20 FY21 FY19 FY20 FY21 Adjusted EBITDA (Loss) Adjusted Operating Expenses as a % of Revenue* as a % of Revenue* (41.0%) (25.0%) (15.8%)
Slide 23: Financial Targets and Goals (Non-GAAP)
Financial Targets and Goals (Non-GAAP) Long-Term Goals Commentary Adj. Gross Margin 50-55% Investments in technology and offering mix projected to drive GM% up P&T as Projecting to continue to increase absolute dollar investments in Product % of Rev. 13-17% & Tech at a decreasing rate Adj. As sales
Slide 24: Appendix
Accolade Appendix
Slide 25: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA
Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and other expenses. We define Adjust
Slide 26: Adjusted Gross Margin GAAP to Non-GAAP Reconciliation
Adjusted Gross Margin GAAP to Non-GAAP Reconciliation
Slide 27: Adjusted EBITDA GAAP to Non-GAAP Reconciliation
Adjusted EBITDA GAAP to Non-GAAP Reconciliation
Slide 28: Adjusted Operating Expenses Reconciliation
Adjusted Operating Expenses Reconciliation
Slide 29: Accolade
Accolade PERSONALIZED HEALTHCARE